See more : PT Bank Permata Tbk (BNLI.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Broncus Holding Corporation (2216.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Broncus Holding Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- UNITED LEASING & INDUSTRIES LT (UNTTEMI.BO) Income Statement Analysis – Financial Results
- Hotel Chocolat Group plc (HCHOF) Income Statement Analysis – Financial Results
- Kemistar Corporation Limited (KEMISTAR.BO) Income Statement Analysis – Financial Results
- Creades AB (CRED-A.ST) Income Statement Analysis – Financial Results
- Valaris Limited (VAL) Income Statement Analysis – Financial Results
Broncus Holding Corporation (2216.HK)
About Broncus Holding Corporation
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 10.26M | 9.41M | 10.89M | 3.26M | 8.07M |
Cost of Revenue | 3.03M | 2.10M | 2.15M | 753.00K | 2.09M |
Gross Profit | 7.23M | 7.32M | 8.74M | 2.51M | 5.98M |
Gross Profit Ratio | 70.47% | 77.71% | 80.27% | 76.89% | 74.06% |
Research & Development | 20.15M | 19.17M | 16.76M | 9.35M | 11.38M |
General & Administrative | 8.93M | 9.23M | 18.55M | 4.02M | 2.76M |
Selling & Marketing | 11.49M | 11.19M | 12.71M | 6.35M | 8.61M |
SG&A | 20.42M | 20.42M | 31.25M | 10.38M | 11.36M |
Other Expenses | -33.34M | -497.00K | -1.84M | 3.35M | 6.08M |
Operating Expenses | 7.23M | 39.09M | 46.17M | 23.08M | 28.82M |
Cost & Expenses | 43.48M | 41.19M | 48.32M | 23.83M | 30.91M |
Interest Income | 6.04M | 2.63M | 161.00K | 76.00K | 119.00K |
Interest Expense | 163.00K | 98.00K | 170.00K | 647.00K | 517.00K |
Depreciation & Amortization | 2.87M | 2.85M | 2.69M | 2.19M | 2.07M |
EBITDA | -25.06M | -25.51M | -233.31M | -45.95M | -29.96M |
EBITDA Ratio | -244.37% | -271.03% | -2,147.13% | -1,423.04% | -372.41% |
Operating Income | -33.22M | -28.36M | -236.54M | -48.57M | -32.13M |
Operating Income Ratio | -323.95% | -301.29% | -2,171.84% | -1,490.30% | -398.09% |
Total Other Income/Expenses | 5.13M | 327.00K | -198.75M | -28.22M | -9.71M |
Income Before Tax | -28.09M | -28.03M | -236.18M | -48.78M | -32.55M |
Income Before Tax Ratio | -273.91% | -297.81% | -2,168.53% | -1,496.90% | -403.23% |
Income Tax Expense | 3.00K | 3.00K | 3.00K | 2.00K | 2.00K |
Net Income | -28.09M | -28.04M | -236.18M | -48.79M | -32.55M |
Net Income Ratio | -273.92% | -297.84% | -2,168.56% | -1,496.96% | -403.26% |
EPS | -0.06 | -0.06 | -0.79 | -0.09 | -0.06 |
EPS Diluted | -0.06 | -0.06 | -0.79 | -0.09 | -0.06 |
Weighted Avg Shares Out | 488.57M | 487.75M | 298.96M | 525.62M | 525.62M |
Weighted Avg Shares Out (Dil) | 488.57M | 487.75M | 298.96M | 525.62M | 525.62M |
Source: https://incomestatements.info
Category: Stock Reports